CAMURUS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 491.6 SEK | +0.70% |
|
-2.27% | -8.62% |
| Apr. 02 | Camurus AB Announces Board Resignations | CI |
| Mar. 05 | Camurus' New Drug Application for Acromegaly Treatment Accepted by US FDA | MT |
| Sales 2024 * | 1.87B 171M | Sales 2025 * | 2.92B 267M | Capitalization | 28.13B 2.57B |
|---|---|---|---|---|---|
| Net income 2024 * | 314M 28.71M | Net income 2025 * | 940M 85.94M | EV / Sales 2024 * | 14 x |
| Net cash position 2024 * | 1.83B 167M | Net cash position 2025 * | 2.82B 258M | EV / Sales 2025 * | 8.68 x |
| P/E ratio 2024 * |
96.5
x | P/E ratio 2025 * |
30.6
x | Employees | 213 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Camurus AB
More press releases
More news
| 1 day | -1.99% | ||
| 1 week | -4.77% | ||
| Current month | -5.62% | ||
| 1 month | -2.48% | ||
| 3 months | -19.50% | ||
| 6 months | +44.98% | ||
| Current year | -10.97% |
1 week
473.00
522.50
1 month
473.00532.50
Current year
417.40599.50
1 year
218.80599.50
3 years
120.00599.50
5 years
61.50599.50
10 years
58.00599.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01-12-31 | |
| Director of Finance/CFO | 51 | 22-01-31 | |
| Chief Tech/Sci/R&D Officer | - | 23-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 09-12-31 | |
| Chief Executive Officer | 61 | 01-12-31 | |
| Director/Board Member | 52 | 20-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 491.6 | +0.70% | 95 224 |
| 24-04-15 | 488.2 | -4.18% | 79,541 |
| 24-04-12 | 509.5 | 0.00% | 33,688 |
| 24-04-11 | 509.5 | +1.19% | 65,099 |
| 24-04-10 | 503.5 | +0.10% | 58,226 |
Delayed Quote Nasdaq Stockholm, April 16, 2024 at 09:07 am EDT
More quotes
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company's products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
488.2
SEK
Average target price
577.2
SEK
Spread / Average Target
+18.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.97% | 2.59B | |
| +28.79% | 676B | |
| +23.66% | 559B | |
| -5.84% | 356B | |
| +15.75% | 320B | |
| +4.32% | 286B | |
| +2.87% | 213B | |
| -0.20% | 207B | |
| -9.24% | 199B | |
| -7.82% | 142B |
- Stock Market
- Equities
- CAMX Stock
